IMMUNOGENETICS

PROF. THOMAS HERRMANN

Institute for Virology and Immunobiology - Chair of Immunology

herrmann-t@vim.uni-wuerzburg.de I +49 931 31 81538 www.virologie.uni-wuerzburg.de/immunologie



SELECTED PUBLICATIONS

Fichtner AS, Karunakaran MM, Gu S, Boughter CT, Borowska MT, Starick L, Nohren A, Gobel TW, Adams EJ, Herrmann T (2020) Alpaca (Vicugna pacos), the first nonprimate species with a phosphoantigen-reactive Vγ9Vδ2 T cell subset.

PNAS 117(12):6697-6707

Karunakaran MM, Willcox CR, Salim M, Paletta D, Fichtner AS, Noll A, Starick L, Nöhren A, Begley CR, Berwick KA, Chaleil RAG, Pitard V, Déchanet-Merville J, Bates PA, Kimmel B, Knowles TJ, Kunzmann V, Walter L, Jeeves M, Mohammed F, Willcox BE, Herrmann T (2020) Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vgamma9Vdelta2 TCR and Is Essential for Phosphoantigen Sensing. Immunity 52(3):487-498.e6

Fichtner AS, Karunakaran MM, Starick L, Truman RW, Herrmann T (2018) The Armadillo (Dasypus novemcinctus): A Witness but Not a Functional Example for the Emergence of the Butyrophilin 3/ Vy9Vδ2 System in Placental Mammals. Frontiers in Immunology 9:265

RESEARCH INTERESTS


Vy9Vδ2 T cells are effectors with antimicrobial and anti-tumor activity. Their eponymous Vy9Vδ2 T-cell antigenreceptor recognizes phosphoantigens (PAg) sensing tumor or host cells. The PAg (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) is found in many eubacteria and in apicomplexa such as Plasmodium spp. and leads to expansion of $Vy9V\delta2$ T cells in infections. The ubiquitous but very weak PAg isopentenyl pyrophosphate (IPP) is increased in tumors, especially after administration of aminobisphosphophonates (e.g. zoledronate) and triggers anti-tumor activity. We aim to understand the molecular basis of recognition of PAgs in infections and to harness the antitumor effector potential of Vy9Vδ2 T cells.


HIGHLIGHTS & OUTLOOK

A key player in $Vy9V\delta2T$ cell-activation is the cell surface molecule butyrophilin (BTN)3A1. Its extracellular domain is very similar to members of the B7

family (e.g. CD80/86). Binding of PAgs to the intracellular B30.2 domain of BTN3A1 leads to a conformational change of the entire molecule, and finally to Vy9Vδ2 T-cell activation by the BTN3A1-expressing cell. This requires cooperation with the BTN3A1 paralogues BTN3A2 and BTN3A3. Until recently, Vy9Vδ2 T cells were found only in primates. We identified and characterized key genes of PAgrecognition (Vy9, Vδ2, and BTN3) and their products in other mammalian species (Fichtner et al., 2018) and newly generated reagents allowed us to identify the alpaca (Vicugna pacos) as the first non-primate species with functional Vy9Vδ2 T cells. Interestingly, alpaca possess only one BTN3, which merges the functions of the three human BTN3s (Fichtner et al., 2020).

We also identified the human BTN2A1 molecule as a new player in PAg-presentation by screening human-rodent radiation hybrids for their capacity of PAg-presentation (Karunakaran et al., 2020). In cooperation with the Willcox group in Birmingham, UK, BTN2A1 binding was shown to the Vv9 gene product and the V-domain of BTN3A1. BTN2A1 and BTN3A1 transferred the capacity of PAg presentation to rodent cells and is aimed to be used for creation of a transgenic mouse model for PAg-reactive Vγ9Vδ2 T cells, which so far can only be studied in primates. The study of the molecular basis of interaction between the butyrophilins and of ligands binding to the $V\gamma9V\delta2$ TCR will also be continued.





Model of Vv9V8 T cell activation. BTN2A1 binds to Vy9 and PAg binding to BTN3A1 induces a conformation of the BTN-complex exposing an unknown ligand(s) to the CDR3s of Vy9V6 TCR. Figure from: An Update on the Molecular Basis of Phosphoantigen Recognition by Vy9Vδ2 T Cells. Herrmann T, Fichtner AS, Karunakaran MM. Cells. 2020 Jun 9;9(6):E1433. doi: 10.3390/cells9061433.

From ZINF Report 2018/2019